We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+27.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$197M
AUM Growth
-$76M
Cap. Flow
-$97.6M
Cap. Flow %
-49.58%
Top 10 Hldgs %
44.5%
Holding
160
New
26
Increased
14
Reduced
15
Closed
66

Top Buys

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$9.39M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$4.07M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$3.73M
4
OTLK icon
Outlook Therapeutics
OTLK
+$3.62M
5
REPL icon
Replimune Group
REPL
+$3.32M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$8.27M
2
INSM icon
Insmed
INSM
+$5.77M
3
MBTC
Nocturne Acquisition Corporation Ordinary Shares
MBTC
+$5.17M
4
BCAB icon
BioAtla
BCAB
+$4.26M
5
ILMN icon
Illumina
ILMN
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 88.67%
2 Financials 5.8%
3 Communication Services 0.42%
4 Industrials 0.36%
5 Materials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
126
Relmada Therapeutics
RLMD
$527M
– –
-8,500
Closed -$315K
RLMD icon
127
PUT
Relmada Therapeutics
RLMD
$527M
– –
-18,200
Closed -$674K
RNAM
128
DELISTED
Avidity Biosciences
RNAM
– –
-150,000
Closed -$2.45M
SDOT icon
129
Sadot Group
SDOT
$12.7M
– –
-886
Closed -$666K
TRVI icon
130
Trevi Therapeutics
TRVI
$2.64B
– –
-1,066,157
Closed -$1.64M
TSVT
131
DELISTED
2seventy bio
TSVT
– –
-140,000
Closed -$2.04M
TWST icon
132
Twist Bioscience
TWST
$7.25B
– –
-68,000
Closed -$2.4M
UBX
133
DELISTED
Unity Biotechnology
UBX
– –
-427,000
Closed -$1.69M
VCEL icon
134
Vericel Corp
VCEL
$2.31B
– –
-80,000
Closed -$1.86M
VEEE icon
135
Twin Vee PowerCats
VEEE
$4.85M
– –
-183
Closed -$165K
VIGL
136
DELISTED
Vigil Neuroscience
VIGL
– –
-15,788
Closed -$144K
VSTM icon
137
Verastem
VSTM
$610M
– –
-250,000
Closed -$2.55M
DHACU
138
DELISTED
Digital Health Acquisition Corp. Unit
DHACU
– –
-150,000
Closed -$1.54M
TTOO
139
DELISTED
T2 Biosystems, Inc
TTOO
– –
-568
Closed -$321K
EIGR
140
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-14,667
Closed -$3.31M
MBTC
141
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
– –
-500,000
Closed -$5.17M
LBBB
142
DELISTED
Lakeshore Acquisition II Corp. Ordinary Shares
LBBB
– –
-200,000
Closed -$2.02M
NSTG
143
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-280,000
Closed -$3.58M
EUCR
144
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
– –
-400,000
Closed -$4.01M
OMEG
145
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
– –
-100,000
Closed -$993K
GIWWW
146
DELISTED
GigInternational1, Inc. Warrant
GIWWW
– –
-50,000
Closed -$3K
LAAAW
147
DELISTED
Lakeshore Acquisition I Corp. Warrant
LAAAW
– –
-150,000
Closed -$30K
RCOR.WS
148
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
– –
-731,561
Closed -$58K
RCOR
149
DELISTED
Renovacor, Inc.
RCOR
– –
-388,845
Closed -$980K
JYAC
150
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-200,000
Closed -$1.99M
3 4 5
6
7

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Altium Capital Management held 160 positions worth $197M, down 28% from $273M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Altium Capital Management withdrew a net $97.6M in Q4 2022, closing 66 positions and reducing 15 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $8.27M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Altium Capital Management opened a new position in Tandem Diabetes Care worth $4.05M.

  • Altium Capital Management's largest Q4 2022 buy was Tandem Diabetes Care: 90,000 shares worth $4.05M.
  • Altium Capital Management added most to Astria Therapeutics in Q4 2022, an estimated $9.39M increase.
  • Altium Capital Management's biggest Q4 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $3.1M.
  • Altium Capital Management fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $8.27M.
  • Altium Capital Management's ten largest holdings make up 45% of its $197M portfolio in Q4 2022.
  • Altium Capital Management opened 26 new positions and closed 66 in Q4 2022.
  • Altium Capital Management's portfolio value fell 28% quarter-over-quarter to $197M.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.